Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Long-Term Investments (2016 - 2025)

Tg Therapeutics has reported Long-Term Investments over the past 5 years, most recently at $59.1 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $59.1 million for Q4 2025, up 7218.81% from a year ago — trailing twelve months through Dec 2025 was $59.1 million (up 7218.81% YoY), and the annual figure for FY2025 was $59.1 million, up 7218.81%.
  • Long-Term Investments for Q4 2025 was $59.1 million at Tg Therapeutics, up from $48.8 million in the prior quarter.
  • Over the last five years, Long-Term Investments for TGTX hit a ceiling of $59.1 million in Q4 2025 and a floor of $808000.0 in Q4 2024.
  • Median Long-Term Investments over the past 4 years was $21.8 million (2022), compared with a mean of $22.2 million.
  • Biggest five-year swings in Long-Term Investments: crashed 65.09% in 2022 and later soared 7218.81% in 2025.
  • Tg Therapeutics' Long-Term Investments stood at $35.5 million in 2021, then crashed by 65.09% to $12.4 million in 2022, then plummeted by 93.49% to $808000.0 in 2024, then soared by 7218.81% to $59.1 million in 2025.
  • The last three reported values for Long-Term Investments were $59.1 million (Q4 2025), $48.8 million (Q3 2025), and $28.6 million (Q2 2025) per Business Quant data.